Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of August 2025, with the specific transaction date being August 5, 2025. The filing serves as a disclosure of share repurchases executed under a pre-existing non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics and Transaction Details
- Shares Purchased: 498,759 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,388.00 GBp; highest price paid was 1,412.50 GBp.
- Average Price: Volume-weighted average price paid was 1,397.84 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (CHIX or BATE).
- Treasury Share Holdings: Following this purchase, GSK holds 238,538,545 ordinary shares in treasury.
- Shares in Issue: 4,076,849,940 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.85% of total voting rights.
Material Changes and Program Status
This transaction is part of GSK's existing buyback programme initiated via a non-discretionary agreement on June 4, 2025. Since the commencement of this agreement, the company has purchased an aggregate of 20,404,162 ordinary shares. The filing does not disclose revenue, profit, cash flow, or debt metrics, as it is a specific disclosure of share repurchase activity rather than a financial results report.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Important Facts for Investor Verification
- Verify the total number of treasury shares held (238,538,545) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the buyback programme initiated on June 4, 2025, to assess future repurchase capacity.
- Note that treasury shares (5.85% of voting rights) do not carry voting rights, which impacts the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules.
- Review the referenced Form 20-F (2024) and Q2 2025 results for comprehensive financial performance data not included in this transaction-specific filing.